Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.7.0.1
Collaboration and License Agreements - Additional Information (Detail)
1 Months Ended 6 Months Ended
Jun. 30, 1998
USD ($)
Jun. 30, 2017
USD ($)
Agreement
Jun. 30, 2016
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Collaboration revenue   $ 4,793,000  
Kowa Pharmaceuticals America Inc [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Non-refundable up-front payment   5,000,000  
Kowa Pharmaceuticals America Inc [Member] | Initiation or Achievement [Member] | Maximum [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Milestone payments   200,000,000  
Janssen Pharmaceutical NV [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty payment   $ 0  
Janssen Pharmaceutical NV [Member] | Maximum [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Percentage of royalty on net sales   8.00%  
Janssen Pharmaceuticals, Inc. [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
License agreement date   Jun. 30, 2010  
Number of development and license agreements | Agreement   2  
DiaTex, Inc. [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Royalty payment   $ 0 $ 0
License agreement date   Jun. 30, 1998  
Monthly license fees $ 2,000    
Potential future development payments $ 800,000    
Development payment   $ 0 $ 0